What is PPD?
Established in 1985, PPD operates as a premier contract research organization (CRO) providing comprehensive services across the drug discovery and development spectrum. By partnering with pharmaceutical, biotechnological, and medical device firms, as well as academic and government institutions, PPD facilitates the transition of therapeutic candidates from laboratory settings to commercial viability. The company's market position is defined by its extensive infrastructure and deep expertise in clinical trial management, which remains essential for stakeholders aiming to optimize time-to-market for life-saving medical innovations. Keywords: Contract Research Organization, Clinical Trial Management, Drug Development, Pharmaceutical Services, Biotechnology Innovation, Healthcare Lifecycle Management, Strategic Capital, Institutional Investment.
How much funding has PPD raised?
PPD has raised a total of $2.2B across 2 funding rounds:
Other Financing Round
$550M
Stock Offering
$1.6B
Other Financing Round (2017): $550M with participation from GIC and Hellman & Friedman
Stock Issuance/Offering (2020): $1.6B, investors not publicly disclosed
Key Investors in PPD
GIC
Founded in 1981, GIC is a sovereign wealth fund managing Singapore's foreign reserves with a mandate to secure the country's financial future through diverse global asset class investments.
Hellman & Friedman
A San Francisco-based private equity firm established in 1984, specializing in buyouts and strategic investments across sectors including healthcare, software, and financial services.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for PPD?
With the support of major institutional backers, PPD is well-positioned to accelerate its strategic initiatives in digital health integration and decentralized clinical trial methodologies. The recent capital injection provides the necessary liquidity to scale operations, potentially through targeted acquisitions or the expansion of its global footprint in emerging markets. As the pharmaceutical industry faces increasing pressure to reduce development costs while maintaining rigorous safety standards, PPD's focus on operational efficiency and data-driven research will likely serve as a primary driver for long-term value creation. The firm remains a critical partner for entities seeking to navigate the evolving regulatory landscape of global healthcare.
See full PPD company page
